Case File
efta-efta00732301DOJ Data Set 9OtherFrom: Jeffrey Epstein <[email protected]>
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00732301
Pages
2
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: Jeffrey Epstein <[email protected]>
To: "gmaxl®instantemail.t-mobile.co.uk" <gmaxl®instantemail.t-mobile.co.uk>
Subject: Fwd: Vivendi/Credit des Alpes/Pharma
Date: Fri, 01 Oct 2010 16:20:32 +0000
Attachments: Agefl.pdf; Tombstone_GVT-Vivendi-Credit_des_Alpes.pdf; CLIP-0F2E5DD9.JPG
talk to me
Forwarded message
From:
Date: 2010/10/1
Subject: Vivendi/Credit des Alpes/Pharma
To: [email protected]
My dear Jeff,
it was really good to see you in such a good shape. I look better --but you certainly great.
Be serious for a minute:
Following the transaction that we closed with Vivendi (mentioned at lunch and of which I am attaching a
description), another European
client mandated my bank Credit des Alpes to identify a possible acquisition in the pharmaceutical and/or medical
appliances and/or medical devices
(practically almost anything that has to do with human health) industries. What our new client really wants to
buy is Ebitda growth. Ideally 20+ % pa.,
which is much more likely to be found in emerging economies than around here. Good target size is Ebitda $
200-400 with little debt (ie. a
transaction value of $1.5-3bn).
In my experience going through the traditional channels of my competitors investment banks has never produced
anything.
I thought that your ideas could be of great help to me and I'd welcome your advice.
I look forward to see you in New York either on the 12th or around the 21st of October. Please let me know if
you'll be there.
Behave,
Fabrizio Cerina
Financial Times. December 10, 2009
CREDIT DES ALPES, Geneva office
Tel.
Fax
CREDIT DES ALPES, Lugano office
Tel.
direct
Fax
direct
EFTA00732301
This message is intended only for the person(s) to which it is addressed and may contain privileged, confidential
and/or insider information. If you have received this communication in error, please notify us immediately by
replying to the message and deleting it from your computer. Any disclosure, copying, distribution, or the taking
of any action concerning the contents of this message and any attachments) by anyone other than the named
recipient(s) is strictly prohibited.
Credit des Alpes SA
To: [email protected]
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments.
EFTA00732302
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Domain
instantemail.t-mobile.co.ukEmail
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.